Patents by Inventor C. Frank Bennett

C. Frank Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR INHIBITING THE ACTIVITY OF MIR-155
    Publication number: 20120035248
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 31, 2008
    Publication date: February 9, 2012
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
    Patent number: 8110558
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: February 7, 2012
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Antisense Modulation of Superoxide Dismutase 1, Soluble Expression
    Publication number: 20120029049
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: January 10, 2011
    Publication date: February 2, 2012
    Applicant: Isis Corporation
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier
  • Method for inhibiting the activity of mir-155
    Patent number: 8106025
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: January 31, 2012
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Compositions and their uses directed to hepcidin
    Patent number: 8076306
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 13, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, C. Frank Bennett, William A. Gaarde, Trisha Lockhart, Robert McKay
  • MODULATION OF PRION EXPRESSION
    Publication number: 20110269818
    Abstract: Disclosed herein are compounds and methods for decreasing PrP and preventing, ameliorating, or treating a prion disease or conformational neurodegenerative disorder, in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to PrP include Creutzfeldt-Jakob disease (CJD); variant Creutzfeldt-Jakob Disease (vCJD); Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia; kuru; Bovine Spongiform Encephalopathy (BSE), e.g. “mad cow disease”; Chronic Wasting Disease (CWD); scrapie; transmissible mink encephalopathy; feline spongiform encephalopathy; ungulate spongiform encephalopathy; Alzheimer's disease; Parkinson's disease; Huntington's disease; and Amyotrophic Lateral Sclerosis (ALS).
    Type: Application
    Filed: August 14, 2009
    Publication date: November 3, 2011
    Applicant: ISIS PHARMACEUTICALS, INC
    Inventors: C Frank Bennett, Gene Hung
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
    Publication number: 20110224277
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 31, 2008
    Publication date: September 15, 2011
    Applicant: REGULUS THERAPEUTICS, LLC.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • MODULATION OF SMAD3 EXPRESSION
    Publication number: 20110213011
    Abstract: Provided are compounds capable of inhibiting SMAD3 and compositions containing same as well as methods using such compounds for treating fibrosis and scarring.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Susan M. Freier, C. Frank Bennett, William A. Gaarde
  • MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION
    Publication number: 20110172296
    Abstract: Provided are compounds capable of inhibiting expression of TGF-beta 1 and compositions containing same as well as methods using such compounds for treating fibrotic diseases including the reduction of scarring resulting from wound healing.
    Type: Application
    Filed: January 12, 2011
    Publication date: July 14, 2011
    Inventors: C. Frank Bennett, Susan M. Freier, Nicholas M. Dean, J. Gordon Foulkes, William A. Gaarde
  • Conjugates For Use In Hepatocyte Free Uptake Assays
    Publication number: 20110171730
    Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.
    Type: Application
    Filed: December 21, 2010
    Publication date: July 14, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
  • MODULATION OF CD40 EXPRESSION
    Publication number: 20110160283
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Application
    Filed: November 20, 2008
    Publication date: June 30, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier
  • Compositions and methods for the modulation of the expression of B7 protein
    Patent number: 7960355
    Abstract: Antisense oligonucleotide compositions which specifically hybridize with nucleic acids encoding B7 proteins, and use of these compositions for inhibiting expression of B7 mRNA.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: June 14, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier
  • Antiviral Oligonucleotides Having a Conserved G4 Core Sequence
    Publication number: 20110124715
    Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 26, 2011
    Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy Vickers, Jacqueline R. Wyatt
  • COMPOUNDS AND METHODS FOR MODULATING PROTEIN EXPRESSION
    Publication number: 20110124591
    Abstract: The present invention provides compounds and methods for modulating expression of a protein, including, but not limited to, modulating splicing of a pre-mRNA to modulate the amount of one or more variants of a protein.
    Type: Application
    Filed: November 13, 2008
    Publication date: May 26, 2011
    Applicant: ISIS Pharmaceuticals Inc.
    Inventor: C. Frank Bennett
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Patent number: 7902163
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: March 8, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier
  • METHOD FOR REDUCING SCARRING DURING WOUND HEALING USING ANTISENSE COMPOUNDS DIRECTED TO CTGF
    Publication number: 20110054004
    Abstract: This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.
    Type: Application
    Filed: August 26, 2009
    Publication date: March 3, 2011
    Inventors: THOMAS A. MUSTOE, NICHOLAS M. DEAN, MARK SISCO, ZOL KRYGER, C. FRANK BENNETT
  • Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
    Patent number: 7897582
    Abstract: Compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: March 1, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M Freier
  • CHIMERIC OLIGOMERIC COMPOUNDS FOR MODULATION OF SPLICING
    Publication number: 20110039334
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Application
    Filed: August 29, 2006
    Publication date: February 17, 2011
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard M. Kole, Casey C. Kopczynski
  • Conjugates for use in hepatocyte free uptake assays
    Patent number: 7884086
    Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: February 8, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
  • COMPOUNDS AND METHODS FOR IMPROVING CELLULAR UPTAKE OF OLIGOMERIC COMPOUNDS
    Publication number: 20100292304
    Abstract: The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake.
    Type: Application
    Filed: October 6, 2008
    Publication date: November 18, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Erich Koller, C. Frank Bennett